Latest filings (excl ownership)
15-12G
Securities registration termination
28 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
25-NSE
Exchange delisting
18 Mar 24
POSASR
Automatic shelf registration (post-effective amendment)
18 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
18 Mar 24
10-K/A
2023 FY
Annual report (amended)
14 Mar 24
8-K
Other Events
14 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
12 Mar 24
DEFA14A
Additional proxy soliciting materials
1 Mar 24
8-K
Other Events
1 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
22 Feb 24
DEFM14A
Proxy related to merger
5 Feb 24
PREM14A
Preliminary proxy related to merger
22 Jan 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
8-K
Entry into a Material Definitive Agreement
22 Dec 23
DFAN14A
Additional proxy materials by non-management
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DFAN14A
Additional proxy materials by non-management
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
DEFA14A
Additional proxy soliciting materials
22 Dec 23
8-K
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
22 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
3 Aug 23
S-3ASR
Automatic shelf registration
21 Jun 23
8-K
Termination of a Material Definitive Agreement
21 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
Latest ownership filings
4
David E. Wheadon
18 Mar 24
4
Denice Torres
18 Mar 24
4
Atul Pande
18 Mar 24
4
LAURIE J OLSON
18 Mar 24
4
JEFFREY M JONAS
18 Mar 24
4
JAMES HEALY
18 Mar 24
4
STEVEN M PAUL
18 Mar 24
4
Andrew Craig Miller
18 Mar 24
4
CHRISTOPHER J COUGHLIN
18 Mar 24
4
Jason Parker Brown
18 Mar 24
4
William Meury
18 Mar 24
4
William P Kane Jr
18 Mar 24
4
Stephen K. Brannan
18 Mar 24
4
Stephen K. Brannan
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
STEVEN M PAUL
4 Mar 24
4
STEVEN M PAUL
26 Feb 24
4
William P Kane Jr
15 Feb 24
4
Stephen K. Brannan
15 Feb 24
4
Jason Parker Brown
15 Feb 24
4
Andrew Craig Miller
15 Feb 24
4
William Meury
15 Feb 24
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
STEVEN M PAUL
12 Feb 24
4
Andrew Craig Miller
12 Feb 24
4
Stephen K. Brannan
12 Feb 24
SC 13G/A
Capital International Investors
12 Feb 24
SC 13G/A
FMR LLC
12 Feb 24
SC 13G/A
Capital International Investors
9 Feb 24
144
Notice of proposed sale of securities
8 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
SC 13G/A
FMR LLC
10 Jan 24
4
Stephen K. Brannan
9 Jan 24
144
Notice of proposed sale of securities
8 Jan 24
4
William P Kane Jr
29 Dec 23
4
William Meury
29 Dec 23
144
Notice of proposed sale of securities
27 Dec 23
4
Stephen K. Brannan
12 Dec 23